Literature DB >> 18408078

Repression of gene expression by unphosphorylated NF-kappaB p65 through epigenetic mechanisms.

Jie Dong1, Eijiro Jimi, Haihong Zhong, Matthew S Hayden, Sankar Ghosh.   

Abstract

Cells from a "knock-in" mouse expressing a NF-kappaB p65 mutant bearing an alanine instead of serine at position 276 (S276A) display a significant reduction of NF-kappaB-dependent transcription, even though the mutant p65 forms appropriate complexes that translocate normally to the nucleus and bind to DNA. Surprisingly, however, instead of the expected embryonic lethality from hepatocyte apoptosis seen in the absence of NF-kappaB activity, the S276A knock-in embryos die at different embryonic days due to variegated developmental abnormalities. We now demonstrate that this variegated phenotype is due to epigenetic repression resulting from the recruitment of histone deacetylases by the nonphosphorylatable form of NF-kappaB into the vicinity of genes positioned fortuitously near NF-kappaB-binding sites. Therefore, unphosphorylated nuclear NF-kappaB can affect expression of genes not normally regulated by NF-kappaB through epigenetic mechanisms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18408078      PMCID: PMC2335313          DOI: 10.1101/gad.1657408

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  31 in total

Review 1.  Position-effect variegation and the genetic dissection of chromatin regulation in Drosophila.

Authors:  Gunnar Schotta; Anja Ebert; Rainer Dorn; Gunter Reuter
Journal:  Semin Cell Dev Biol       Date:  2003-02       Impact factor: 7.727

2.  Differential Pax6 promoter activity and transcript expression during forebrain development.

Authors:  Tonya R Anderson; Eva Hedlund; Ellen M Carpenter
Journal:  Mech Dev       Date:  2002-06       Impact factor: 1.882

Review 3.  Pax genes and eye organogenesis.

Authors:  Franck Pichaud; Claude Desplan
Journal:  Curr Opin Genet Dev       Date:  2002-08       Impact factor: 5.578

4.  Targeted mutation of TNF receptor I rescues the RelA-deficient mouse and reveals a critical role for NF-kappa B in leukocyte recruitment.

Authors:  E Alcamo; J P Mizgerd; B H Horwitz; R Bronson; A A Beg; M Scott; C M Doerschuk; R O Hynes; D Baltimore
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

5.  Female mice heterozygous for IKK gamma/NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti.

Authors:  C Makris; V L Godfrey; G Krähn-Senftleben; T Takahashi; J L Roberts; T Schwarz; L Feng; R S Johnson; M Karin
Journal:  Mol Cell       Date:  2000-06       Impact factor: 17.970

6.  NEMO/IKK gamma-deficient mice model incontinentia pigmenti.

Authors:  M Schmidt-Supprian; W Bloch; G Courtois; K Addicks; A Israël; K Rajewsky; M Pasparakis
Journal:  Mol Cell       Date:  2000-06       Impact factor: 17.970

7.  The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1.

Authors:  Haihong Zhong; Michael J May; Eijiro Jimi; Sankar Ghosh
Journal:  Mol Cell       Date:  2002-03       Impact factor: 17.970

8.  Severe liver degeneration and lack of NF-kappaB activation in NEMO/IKKgamma-deficient mice.

Authors:  D Rudolph; W C Yeh; A Wakeham; B Rudolph; D Nallainathan; J Potter; A J Elia; T W Mak
Journal:  Genes Dev       Date:  2000-04-01       Impact factor: 11.361

9.  Aniridia-associated translocations, DNase hypersensitivity, sequence comparison and transgenic analysis redefine the functional domain of PAX6.

Authors:  D A Kleinjan; A Seawright; A Schedl; R A Quinlan; S Danes; V van Heyningen
Journal:  Hum Mol Genet       Date:  2001-09-15       Impact factor: 6.150

10.  Two waves of nuclear factor kappaB recruitment to target promoters.

Authors:  S Saccani; S Pantano; G Natoli
Journal:  J Exp Med       Date:  2001-06-18       Impact factor: 14.307

View more
  71 in total

Review 1.  Selectivity of the NF-{kappa}B response.

Authors:  Ranjan Sen; Stephen T Smale
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-10-14       Impact factor: 10.005

Review 2.  NF-κB as a target for oncogenic viruses.

Authors:  Shao-Cong Sun; Ethel Cesarman
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

3.  IkappaBeta, a nuclear IkappaB protein, positively regulates the NF-kappaB-mediated expression of proinflammatory cytokines.

Authors:  Shumpei Yamauchi; Hiroaki Ito; Atsushi Miyajima
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-14       Impact factor: 11.205

Review 4.  NF-κB, the first quarter-century: remarkable progress and outstanding questions.

Authors:  Matthew S Hayden; Sankar Ghosh
Journal:  Genes Dev       Date:  2012-02-01       Impact factor: 11.361

5.  Regulation and function of nuclear IκBα in inflammation and cancer.

Authors:  Ivana Vancurova; Ales Vancura
Journal:  Am J Clin Exp Immunol       Date:  2012-05-25

6.  Epigenetic control: slow and global, nimble and local.

Authors:  Christine S Cheng; Tracy L Johnson; Alexander Hoffmann
Journal:  Genes Dev       Date:  2008-05-01       Impact factor: 11.361

Review 7.  Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases.

Authors:  Ilse M E Beck; Wim Vanden Berghe; Linda Vermeulen; Keith R Yamamoto; Guy Haegeman; Karolien De Bosscher
Journal:  Endocr Rev       Date:  2009-11-04       Impact factor: 19.871

8.  Talking to histone: methylated RelA serves as a messenger.

Authors:  Xiao-Dong Yang; Lin-Feng Chen
Journal:  Cell Res       Date:  2011-02-01       Impact factor: 25.617

9.  Virally delivered, constitutively active NFκB improves survival of injured retinal ganglion cells.

Authors:  Galina Dvoriantchikova; Steve Pappas; Xueting Luo; Marcio Ribeiro; Dagmara Danek; Daniel Pelaez; Kevin K Park; Dmitry Ivanov
Journal:  Eur J Neurosci       Date:  2016-09-13       Impact factor: 3.386

10.  Thr435 phosphorylation regulates RelA (p65) NF-kappaB subunit transactivation.

Authors:  John M O'Shea; Neil D Perkins
Journal:  Biochem J       Date:  2010-02-24       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.